Itovebi

Inavolisib, the active ingredient in Itovebi, is a PI3K inhibitor presented as an oral formulation for oral use. It targets the PI3K/AKT signaling pathway and is investigated for the treatment of certain solid tumours in adult oncology patients.

GNH USA supplies Itovebi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards, provides regulatory‑approved batches for clinical and commercial use, and ensures consistent product availability.

Itovebi acts on the PI3K/AKT pathway and is evaluated in oncology settings.

- PIK3CA‑mutated breast cancer: improves disease control when combined with endocrine therapy. - Advanced solid tumours with PI3K pathway activation: used in clinical trials to assess tumor response. - Hormone receptor‑positive metastatic breast cancer: studied as part of combination regimens to extend progression‑free survival.

Adverse reactions have been observed in clinical studies of Inavolisib.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Fatigue: reduced energy levels. - Decreased appetite: reduced food intake. - Hyperglycemia: elevated blood glucose levels. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Severe hyperglycemia: may require medical intervention. - Pneumonitis: inflammation of lung tissue. - Hepatic toxicity: significant liver enzyme elevation. - Interstitial lung disease: rare pulmonary complications. - Stevens‑Johnson syndrome: severe skin reaction. - Thrombocytopenia: marked reduction in platelet count.

Safety considerations should be observed before and during treatment with Itovebi.

- Monitor blood glucose: patients may develop hyperglycemia. - Assess liver function: risk of hepatic enzyme elevation. - Evaluate for infections: immunosuppression can increase infection risk. - Avoid use in uncontrolled diabetes: may exacerbate glycemic control. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Potential drug interactions require careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase Inavolisib exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Antidiabetic agents: concurrent use may necessitate dose adjustment due to hyperglycemia risk.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise plasma levels. - Antacids containing aluminum or magnesium: could affect oral absorption. - Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for myopathy.